Market Research Report
Nontuberculous Mycobacteria Infection (NTM) - Epidemiology forecast 2030
|Published by||DelveInsight Business Research LLP||Product code||923585|
|Published||Content info||100 Pages
Delivery time: 1-2 business days
|Nontuberculous Mycobacteria Infection (NTM) - Epidemiology forecast 2030|
|Published: February 1, 2020||Content info: 100 Pages||
DelveInsight's 'Nontuberculous Mycobacteria Infection (NTM) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Nontuberculous Mycobacteria Infection (NTM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nontuberculous Mycobacteria Infection (NTM) is caused by nontuberculous mycobacteria which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.
The report covers the details of conventional and current medical therapies available in the NTM market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.
Study Period: 2017-2030.
The Nontuberculous Mycobacteria Infection epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool, treatable patient pool and the prevalence based on various parameters such as species type and severity in the US, EU5 and Japan.
According to DelveInsight, the prevalent population of NTM in 7MM is expected to increase at a CAGR of 0.6% for the study period i.e. 2017-2030.
United States has the highest number of prevalent cases of NTM infections among all the 7MM countries.
According to a study by Wagner et al. (2014), the prevalence of PNTM in Europe ranged from 5.9 per 100,000 in Spain to 6.5 per 100,000 in the UK.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed prevalent cases, total treatable population, prevalence based on species, and prevalence based on severity) scenario of Nontuberculous Mycobacteria Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
The Nontuberculous Mycobacteria Infection report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
The NTM infections epidemiology report will allow the user to -